. Author manuscript; available in PMC: 2009 Dec 8.

Published in final edited form as: Proteomics Clin Appl. 2009 Jul 1;3(7):810–820. doi: 10.1002/prca.200800242

Table 3.

Characteristics of protease inhibitors identified by LC-ESI-MS/MS

Protease inhibitor	Accession no.	Target enzyme^a)	Band ID
Alpha-2-macroglobulin-like protein 1	Q6ZW52	Chymotrypsin, subtilisin A, papain, thermolysin	1, 4, 6
Alpha-1-antitrypsin	P01009	Elastase-1, elastase-2, cathepsin G, thrombin, plasmin, kallikrein-related peptidase 4	2, 3, 4, 5, 6, 8, 11, 12, 15
Leukocyte elastase inhibitor	P30740	Elastase-2, cathepsin G, myeloblastin	2, 3, 4, 5, 6, 7, 8, 14
Plasma protease C1 inhibitor	P05155	Complement component activated C1r and C1s	4, 12
Alpha-1-antichymotrypsin	P01011	Kallikrein-related peptidase 14, cathepsin G	4, 6
Cystatin-SA	P09228	Cysteine protease	5
Angiotensinogen	P01019	Unknown	6, 7
Kininogen-1	P01042	Cysteine proteases (cathepsin L)	6
Neuroserpin	Q99574	uPA, tPA, plasmin	7, 8
Metalloproteinase inhibitor 1	P01033	MMPs	16

^a)

Based on information available at the MEROPS website (http://merops.sanger.ac.uk/).